LLYNYSEPharmaceutical PreparationsFiscal year ends December 31

ELI LILLY & Co

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$1240.34−16.69 (-1.33%)

Close on Oct 19, 2026

Market cap: $1.11T
P/E (TTM): 41.6
Dividend yield: 0.50%

Debt

Borrowings on the balance sheet, Jun 30, 2026

Total debt

$54.91B

$7.05B due within a year

Net debt

$45.96B

After $8.95B of cash

Implied interest rate

2.35%

FY2025 interest ÷ average debt

Interest coverage

–

FY2025 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, USD

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Eli Lilly's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Eli Lilly's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Oct 16, 1997
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is LLY.

Revenue growth49.6% · median 5.6%

Gross margin83.4% · median 72.2%

Net margin33.5% · median 8.3%

Company	Revenue	Growth
LLY	$79.67B	+49.6%
MRK	$66.57B	+4.6%
ABBV	$64.39B	+10.4%
PFE	$63.70B	-0.2%
ABT	$45.13B	+6.6%
NVO	–	–

Company

Next earnings (est.): Oct 29, 2026, before open
Exchange: NYSE
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 50,000
Held by institutions: 83.7%
Auditor: Ernst & Young LLP
SEC CIK: 59478

Advertisement
300 × 250